drugset / Trial / NCT07335796
A Study of BMS986365 in Combination With Degarelix in People With Prostate Cancer
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to find out whether BMS986365 in combination with degarelix, given before standard surgical treatment (radical prostatectomy), is a safe and effective treatment that causes few or mild side effects for people who have localized high-risk prostate cancer.
Timeline
- Start
- 2026-01-09
- Primary completion
- 2030-01-09
- Completion
- 2030-01-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CRAVACITINIB | Small molecule | — | — |
| Subject | Degarelix | Other / unclassified | — | — |